Glycogen synthase kinase 3beta induces cell cycle arrest in a cyclin D1-dependent manner in human lung adenocarcinoma

Jian-Sha Li1, Min Zhu, Dan Tian

  • 1Department of Pathology, Tongji Medical College, Huazhong University of Science and Technology, and Key Laboratory of Pulmonary Disease of Ministry of Health of China, Wuhan, China.

Insights

Glycogen synthase kinase 3beta (GSK3beta) activity inhibits cell growth in lung cancer cells. Enhancing GSK3beta reduced cell numbers and promoted G1 cell cycle arrest, suggesting a growth-inhibitory role.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Glycogen synthase kinase 3beta (GSK3beta) is implicated in cell proliferation.
  • Previous studies on GSK3beta's role in cell proliferation have yielded conflicting results across different cell lines and stimuli.

Purpose of the Study:

  • To investigate the direct effect of GSK3beta on cell growth in the human lung adenocarcinoma cell line A549.
  • To elucidate the mechanism by which GSK3beta influences cell cycle progression in A549 cells.

Main Methods:

  • Transient transfection of A549 cells with constitutively active (S9A-GSK3beta) and dominant-negative (KM-GSK3beta) GSK3beta mutant plasmids.
  • Cell counting, flow cytometry, and Western blot analysis were performed 24 hours post-transfection.

Main Results:

  • Enhanced GSK3beta activity led to a significant decrease in A549 cell number.
  • Increased GSK3beta activity resulted in a higher percentage of cells in the G1 phase of the cell cycle.
  • The expression of cyclin D1 was downregulated by GSK3beta in A549 cells.

Conclusions:

  • GSK3beta may induce G1 cell cycle arrest in A549 lung adenocarcinoma cells.
  • This cell cycle arrest appears to be dependent on the regulation of cyclin D1 expression.
  • GSK3beta potentially plays a growth-inhibitory role in A549 lung cancer cells.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.